Assessing Drug Efficacy After Multiple Negative Trials—Gepirone’s Journey Through the FDA

JAMA Psychiatry · Published 2026-06-24 · DOI 10.1001/jamapsychiatry.2026.1438

Authors (4)

Erick H. Turner, John H. Powers, Rosa Y. Ahn-Horst, Aaron S. Kesselheim

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Turner, E., Powers, J., Ahn-Horst, R., et al. (2026). Assessing Drug Efficacy After Multiple Negative Trials—Gepirone’s Journey Through the FDA. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2026.1438

Related articles

• Optimizing Study Design for Clinically Useful Peripheral Molecular Biomarker Discovery in Psychiatry · JAMA Psychiatry · 2026 · Same journal
• Error in Table · JAMA Psychiatry · 2026 · Same journal
• Medication and Procedural Abortion and Risk of Psychotropic Medication Use · JAMA Psychiatry · 2026 · Same journal
• Electroencephalography Microstates—A Biomarker for Psychosis? · JAMA Psychiatry · 2026 · Same journal
• Deconstructing Social Functioning in Psychosis Risk—From Prediction to Recovery · JAMA Psychiatry · 2026 · Same journal
• Confounding and Circularity in Actigraphy Prediction · JAMA Psychiatry · 2026 · Same journal
• Psychedelics Trials and Outcomes—A Closer Look—Reply · JAMA Psychiatry · 2026 · Same journal
• JAMA Psychiatry · JAMA Psychiatry · 2026 · Same journal
• Connectivity- vs Scalp-Based Targeting of Accelerated Transcranial Magnetic Stimulation for Depression · JAMA Psychiatry · 2026 · Same journal
• Error in Visual Abstract · JAMA Psychiatry · 2026 · Same journal